-
Chile Expands Financial Coverage for AbbVie’s RSV Prophylaxis Synagis
•
Chile’s Ministry of Health (MINSAL) has announced an immediate expansion in the coverage under its Financial Protection System for High-Cost Diagnosis and Treatments for AbbVie’s (NYSE: ABBV) respiratory syncytial virus (RSV) prophylaxis, Synagis (palivizumab). The biologic drug is now provided free of charge to families of infants weighing under 2.5…
-
Silence Therapeutics Receives $4 Million Milestone Payment from Hansoh Pharmaceutical
•
UK-based Silence Therapeutics plc (NASDAQ: SLN) has announced the receipt of a $4 million milestone payment from China’s Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) as part of their ongoing collaboration. The specific details of the milestones achieved have not been disclosed, marking a confidential advancement in their joint efforts.…
-
Harbour BioMed Reports First-Ever Profit in H1 2023 Interim Financial Results
•
Harbour BioMed (HKG: 2142), a biotech company with operations in Suzhou, China, Cambridge in the US, and the Netherlands, has announced its interim financial results for the period ending June 30, 2023. In a preliminary review of unaudited figures, the company reported a net profit for the first time, expecting…
-
InnoCare Pharma and ArriVent Biopharma Partner on SHP2 Inhibitor and EGFR Inhibitor Combination
•
China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced a clinical development collaboration with US-based ArriVent Biopharma Inc. The partnership aims to evaluate the combination of InnoCare’s novel SHP2 allosteric inhibitor, ICP-189, with ArriVent’s furmonertinib, a highly brain-penetrant and broadly active mutation-selective EGFR inhibitor. Combining ICP-189 and Furmonertinib for Solid…
-
GSK’s Cabotegravir Receives NMPA Approval for HIV Treatment in China
•
The National Medical Products Administration (NMPA) has granted marketing approval for GlaxoSmithKline’s (GSK, NYSE: GSK) cabotegravir, a significant development in HIV treatment options. Both the injection and tablet dosage forms of the drug have been approved for use in China. Cabotegravir: An Innovative INSTI for HIV TreatmentCabotegravir is an integrase…
-
Beijing Tinavi Medical’s Knee Replacement Navigation System Approved by NMPA
•
Beijing Tinavi Medical Technologies Co., Ltd (SHA: 688277) has received marketing approval from the National Medical Products Administration (NMPA) for its innovative navigation and positioning system designed for knee joint replacement surgery. This marks the 218th innovative product designation granted by China’s NMPA. Innovative 6-DOF Robotic Arm Technology in Knee…
-
GeneQuantum Healthcare and Aimed Bio Expand Partnership to Develop Five Novel ADC Drugs
•
China-based GeneQuantum Healthcare has unveiled a new agreement to expand its existing partnership with South Korea-based biotech firm Aimed Bio. The collaboration will see the two companies jointly develop up to five novel antibody drug conjugate (ADC) drugs, with the specific molecular and disease targets undisclosed. This expansion follows last…
-
BeiGene’s Brukinsa Receives US FDA Review for Relapsed/Refractory Follicular Lymphoma sNDA
•
China-based biotechnology company BeiGene (NASDAQ: BGNE) has announced that the US Food and Drug Administration (FDA) has accepted for review a new supplemental new drug application (sNDA) for its Bruton’s tyrosine kinase (BTK) inhibitor, Brukinsa (zanubrutinib). The application seeks to add a new indication for the treatment of adults with…
